zepbound eli lilly - Search News

Weight Loss Drug Demand Drives Eli Lilly Sales

Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024

Eli Lilly's profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker debuted a mostly better-than-expected 2025 forecast.

Hosted on MSN · 9h

Eli Lilly beats on earnings even as weight loss, diabetes drug sales fall short

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soared. The company's quarterly earnings topped Wall Street estimates,

Reuters · 6h

Lilly reassures investors that weight-loss drug demand is strong, shares rise

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its popular diabetes and weight-loss treatments in new markets.

Eli Lilly Stock Rises

The Motley Fool on MSN · 7h

Why Eli Lilly Stock Popped on Thursday

Eli Lilly ( LLY 3.89%) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in this morning's Q4 earnings report. Heading into the report, analysts forecast Lilly would earn $5.08 per share on sales of $13.4 billion. As it turns out, Lilly earned $5.32 per share in Q4, and sales were $13.5 billion.

Wall Street Journal · 14h

Eli Lilly Stock Rises After Earnings Beat Forecasts

Eli Lilly, the world’s biggest drugmaker by market value, reported higher-than-expected quarterly profit and issued a bullish earnings forecast. Sales of weight-loss drug Zepbound and diabetes drug Mounjaro rose in the fourth quarter.

Kiplinger on MSN · 7h

Eli Lilly Stock Rises After Profit, Outlook Top Expectations

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 guidance. Here's what you need to know.

7hon MSN

Lilly's profit forecast bring investors some relief amid Zepbound miss

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, a move investors said eases some concerns ...

BioSpace6h

After Lilly Powers Up Zepbound Supply, Analyst Wonders if Build Out Is ‘Over Our Skis’

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scaliaasked CEO David Ricks if the company ...

With Zepbound Not Matching Expectations, Should Investors Give Up on Eli Lilly?

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

7hon MSN

Lilly’s Mounjaro and Zepbound contribute to big revenue boost, drugmaker says

Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

10h

Mounjaro and Zepbound Sales Soar, Pushing Eli Lilly's (LLY) Q4 Revenue to New Highs

Eli Lilly posts robust Q4 earnings as Mounjaro and Zepbound sales more than double, lifting full-year revenue by 32% ...

Eli Lilly Q4 Earnings: Now The Magical $1 Trillion Dollar Market Cap Is In Sight

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

11h

Eli Lilly Q4 Earnings: Strong Demand For Mounjaro But Prices Dip, Forecasts Over 30% Jump In 2025 Sales On Newer Medicines

Eli Lilly's Q4 revenue surged 45% to $13.53 billion, fueled by Mounjaro and Zepbound. 2025 guidance forecasts up to $61 ...

Eli Lilly Up 13.3% in 2025: Stock Soars as New Breakthroughs Set to Fuel Explosive Growth

Eli Lilly is setting the stage for a strong 2025, with its fourth-quarter results and forward guidance reflecting solid ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results